Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents

Acta Biomaterialia

Volumn 6, Issue 2, 2010, Pages 534-546

  Gong, Feirong ^a   Cheng, Xiaoyan ^a   Wang, Shanfeng ^b   Zhao, Yanchao ^a   Gao, Yun ^a   Cai, Haibo ^c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b University of Tennessee Knoxville   (United States)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Arsenic trioxide (As2O3); Biodegradability; Heparin; Restenosis; Stent

Indexed keywords

BIODEGRADABILITY; BIODEGRADABLE POLYMERS; BLOOD VESSELS; DEGRADATION; PATHOLOGY; PLASTIC COATINGS; POLYSACCHARIDES; STENTS;

ARSENIC TRIOXIDE (AS2O3); BARE METALS; BIODEGRADABLE COATINGS; COATING MATERIAL; L-LACTIDE; METAL STENTS; PORCINE CORONARY ARTERY; RESTENOSIS; STENT COATINGS; SYNTHESISED;

DISEASES;

5 METHYL 5 BENZYLOXYCARBONATE 1,3 DIOXAN 2 ONE; ARSENIC TRIOXIDE; COPOLYMER; DRUG CARRIER; DRUG VEHICLE; HEPARIN; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG;

ADSORPTION KINETICS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABILITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; DRUG RELEASE; FOREIGN BODY REACTION; HEPARINIZATION; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; IMMOBILIZATION; IN VITRO STUDY; IN-STENT RESTENOSIS; INFLAMMATION; INTERMETHOD COMPARISON; LOCAL THERAPY; MALE; MATERIAL COATING; MORPHOMETRICS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; SURFACE PROPERTY; SWINE; THROMBOCYTE ADHESION; THROMBOGENICITY; THROMBOPLASTIN TIME; THROMBOSIS;

SUS;

EID: 72049107725     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2009.07.013     Document Type: Article

References (52)

1. Fattori R., and Piva T. Drug-eluting stents in vascular intervention. The Lancet 361 (2003) 247-249
2. Venkatraman S., and Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J Control Release 120 (2007) 149-160
3. Sousa J.E., Costa M.A., and Sousa A.G.M.R. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107 (2003) 381-383
4. Stone G.W., Ellis S.G., and Cox D.A. A polymer-based, paclitaxel-eluting stent in patients with coronary arteries diseases. New Eng J Med 350 (2004) 221-231
5. Suzuki T., Kopia G., and Hayashi S.-I. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
6. Carter A.J., Aggarwal M., and Kopia G.A. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 (2004) 617-624
7. Drachman D.E., Edelman E.R., and Seifert P. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over 6 months. J Am Coll Cardiol 36 (2000) 2325-2332
8. Farb A., Heller P.F., and Shroff S. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
9. Virmani R., Liistro F., and Stankovic G. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
10. Pfisterer M., Brunner L., Rocca H.P., and Buser P.T. Late clinical events after clopidrogel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 48 (2006) 2584-2591
11. Stone G.W., Moses J.W., and Ellis S.G. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. New Eng J Med 356 (2007) 998-1008
12. Mauri L., Hsieh W.H., and Massaro J.M. Stent thrombosis in randomized clinical trials of drug-eluting stents. New Eng J Med 356 (2007) 1020-1029
13. Eisenstein E.L., Anstrom K.J., and Kong D.F. Clopidrogel use and long term clinical outcomes after drug-eluting stent implantation. J Am Med Assoc 297 (2007) 159-168
14. Kotani J., Awata M., and Nanto S. Incomplete neo-intimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
15. Ong A.T.L., and Serruys P.W. Technology insight: an overview of research in drug-eluting stents. Nat Clin Prac Cardiovasc Med 2 (2005) 647-658
16. Welt F.G., and Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc 22 (2002) 1769-1776
17. Capila I., and Linhardt R.J. Heparin protein interactions. Angew Chem Inter Ed 41 (2002) 390-412
18. DeScheerder I., Wang K., Wilczek K., Meuleman D., VanAmsterdam R., Vogel G., et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 95 (1997) 1549-1553
19. Blezer R., Cahalan L., and Cahalan P.T. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation. Blood Coagul Fibrin 9 (1998) 435-440
20. Yang W., Ge J., Liu H., Zhao K., Liu X., Qu X., et al. Arsenic trioxide eluting stent reduces neointimal formation in a rabbit iliac artery injury model. Cardiovas Res 72 (2006) 483-493
21. Al-Azemi Talal.F., and Kirpal S.B. Novel functional polycarbonate by lipase-catalyzed ring-opening polymerization of 5-methyl-5-benzyloxycarbonyl-1,3-dioxan-2-one. Macromolecules 32 (1999) 6536-6540
22. Jee K.S., Park H.D., Park K.D., Kim Y.H., and Shin J.W. Heparin conjugated polylactide as a blood compatible material. Biomacromolecules 5 (2004) 1877-1881
23. Xu F.J., Li Y.L., Kang E.T., and Neoh K.G. Heparin-coupled poly(poly(ethylene glycol) monomethacrylate)-Si(111) hybrids and their blood compatible surfaces. Biomacromolecules 6 (2005) 1759-1768
24. Wang S., Kempen D.H., Simha N.K., Lewis J.L., Windebank A.J., Yaszemski M.J., et al. Photo-cross-linked hybrid polymer networks consisting of poly(propylene fumarate) and poly(caprolacton fumarate): controlled physical properties and regulated bone and nerve cell responses. Biomacromolecules 9 (2008) 1229-1241
25. Wang S., Yaszemski M.J., Knight A.M., Gruetzmacher J.A., Windebank A.J., and Lu L. Photo-crosslinked poly(ε-caprolactone fumarate) networks for guided peripheral nerve regeneration: material properties and preliminary biological evaluations. Acta Biomater 5 (2009) 1531-1542
26. 2™ drug-eluting stent. J Biomed Mater Res 71 A (2004) 625-634
27. Dibra A., Kastrati A., and Mehilli J. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. Cath Cardiovasc Interven 65 (2005) 374-380
28. Hara H., Nakamura M., Palmaz J.C., and Schwartz R.S. Role of stent design and coatings on restenosis and thrombosis. Adv Drug Delivery Rev 58 (2006) 377-386
29. Park K., Mao F.W., and Park H. Morphological characterization of surface-induced platelet activation. Biomaterials 11 (1990) 24-31
30. Wang D.-A., Ji J., Gao C.-Y., Yu G.-H., and Feng L.-X. Surface coating of stearyl poly(ethylene oxide) coupling-polymer on polyurethane guiding catheters with poly(ether urethane) film-building additive for biomedical applications. Biomaterials 22 (2001) 1549-1562
31. Hardhammar P.A., van Beusekom H.M.M., Emanuelsson H.U., Hofma S.H., Albertsson P.A., Verdouw P.D., et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 93 (1996) 423-430
32. Tamai H., Igaki K., and Kyo E. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 (2000) 399-404
33. Joner M., Nakazawa G., Finn A.V., Quee S.C., Coleman L., Acampado E., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52 (2008) 333-342
34. Finn A.V., Kolodgie F.D., Harnek J., Guerrero L.J., Acampado E., Tefera K., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
35. Hofma S.H., van der Giessen W.J., and van Dalen B.M. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
36. Togni M., Windecker S., and Cocchia R. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
37. Sousa J.E., Costa M.A., and Farb A. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans. Circulation 110 (2001) e5-e6
38. Kang I.K., Kwon O.H., Kim M.K., Lee Y.M., and Sung Y.K. In vitro blood compatibility of functional group grafted and heparin-immobilized polyurethanes prepared by plasma glow discharge. Biomaterials 18 (1997) 1099-1107
39. Koromila G., Michanetzis G.P.A., Missirlis Y.F., and Antimisiaris S.G. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on hemocompatibility. Biomaterials 27 (2006) 2525-2533
40. Beythien C., Gutensohn K., Bau J., Hamm C.W., Kuhnl P., Meinertz T., et al. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Thromb Res 94 (1999) 79-86
41. Christensen K., Larsson R., Emanuelsson H., Elgue G., and Larsson A. Improved blood compatibility of a stent graft by combining heparin coating and abciximab. Thromb Res 11 (2005) 245-253
42. Riedl C.R., Witkowski M., Plas E., and Pflueger H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int J Antimicrob Ag 19 (2002) 507-510
43. De Scheerder I.K., Wilczek K.L., and Verbeken E.V. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 114 (1995) 105-114
44. Lincoff M.A., Furst J.G., Ellis S.G., Tuch R.J., and Topol E.J. Sustained local delivery of Dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 808-816
45. Nakazawa G., Finn A.V., John M.C., Kolodgie F.D., and Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 100 8B (2007) 36M-44M
46. Schwartz R.S., Holmes Jr. D.R., and Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20 (1992) 1284-1293
47. Karas S.P., Gravanis M.B., Santorian E.C., Robinson K.A., Anderberg K.A., and King S.B. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20 (1992) 467-474
48. Zeymer U., Fishbein M.C., Forrester J.S., and Cercek B. Proliferating cell nuclear antigen immunohistochemistry in rat aorta after balloon denudation: comparison with thymidine and bromodeoxyuridine labeling. Am J Pathol 141 (1992) 685-690
49. Braun-Dullaeus R.C., Mann M.J., and Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98 (1998) 82-89
50. Ellis J.T., Kilpatrick D.L., Consigny P., Prabhu S., and Hossainy S.F.A. Therapy considerations in drug-eluting stents. Crit Rev Ther Drug Carr Sys. 22 (2004) 1-25
51. Castagna M.T., Mintz G.S., Leiboff B.O., Ahmed J.M., Mehran R., Satler L.F., et al. The contribution of mechanical problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090-consecutive in-stent restenosis lesions. Am Heart J 142 (2001) 970-974
52. Sabate M., Costa M.A., Kozuma K., Kay I.P., van der Giessen W.J., Coen V.L., et al. Geographic miss: a cause of treatment failure in radiooncology applied to intracoronary radiation therapy. Circulation 101 (2000) 2467-2471